Fourth quarter 2016 compared to 2015, Group
» Group net sales increased by 168% to SEK 1,007,759 (375,368).
» Other operating income amounted to SEK 821,447 (1,849,848) and is related to capitalized development costs.
» Loss for the period amounted to SEK -18,454,211 (-14,148,843).
» Earnings per share (weighted average) amounted to SEK -1,16 (-0.89).
Twelve months 2016, compared to 2015, Group
» Group net sales increased by 137% to SEK 2,405,614 (1,016,462).
» Other operating income amounted to SEK 1,859,976 (5,628,598) and is related to capitalized development costs.
» Loss for the period amounted to SEK -61,667,464 (-43,974,662).
» Earnings per share (weighted average) amounted to SEK -3,87 (-3,52).
» Equity per share was SEK 3,05 (6,89).
» Equity ratio was 80,8% (93,0).
Significant events during the fourth quarter
» Episurf Medical achieves milestone of 150th Implant.
» Episurf Medical’s 50th Episealer® Femoral Twin Implant demonstrates rapid clinical adoption.
» Touch surgery released Episealer surgical knee training simulations in collaboration with Episurf Medical.
Significant events after the fourth quarter
» Episurf Medical’s CEO Rosemary Cunningham Thomas steps down – search for new CEO initiated.
» Episurf Medical is expanding Its Clinical Advisory Board.
» Episurf Medical announces an up to approx. SEK 120 million rights issue subject to EGM approval and brings forward date of year-end report; Dennis Stripe to act as executive chairman.
» Episurf Medical obtains its first granted patents in China
» Episurf Medical’s 3D-based damage assessment tool: positive development in US patenting
Click on the link to download the full report >> http://episurf.com/investors/reports/
For more information, please contact:
Pål Ryfors, acting CEO, Episurf Medical
Tel: +46 (0) 709 62 36 69
E-mail: pal.ryfors@episurf.com
